Value Creation Co.,Ltd. (TYO:9238)

Sage Therapeutics Balance Sheet

Financials in millions JPY. Fiscal year is March - February.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2021
Period Ending	May 31, 2025	Feb 28, 2025	Feb 29, 2024	Feb 28, 2021
Cash & Equivalents	831.42	1,139	1,212	482.12
Cash & Short-Term Investments	831.42	1,139	1,212	482.12
Cash Growth	-	-6.05%	151.45%	-
Receivables	3,137	2,730	2,236	1,127
Prepaid Expenses	23.41	25.78	10.74	-
Other Current Assets	264.53	45.8	46.05	53.9
Total Current Assets	4,256	3,941	3,505	1,663
Property, Plant & Equipment	88.84	90.18	8.71	16.57
Long-Term Investments	305.4	206.26	74	-
Other Intangible Assets	20.45	21.82	27.27	-
Long-Term Deferred Tax Assets	-	11.59	11.53	-
Other Long-Term Assets	0	34.23	1.54	24.31
Total Assets	4,791	4,305	3,628	1,704
Accounts Payable	2,823	2,430	1,762	911.31
Accrued Expenses	104.48	83.38	56.64	-
Short-Term Debt	100	100	100	222.19
Current Portion of Long-Term Debt	218.44	214.39	243.22	-
Current Income Taxes Payable	39.16	20.05	48.71	-
Current Unearned Revenue	16	16.35	13.1	-
Other Current Liabilities	492.13	483.61	515.71	96.83
Total Current Liabilities	3,793	3,348	2,739	1,230
Long-Term Debt	366.75	375.37	379.78	423.56
Other Long-Term Liabilities	-	-	0	-
Total Liabilities	4,160	3,723	3,119	1,654
Common Stock	157.84	157.84	157.84	50.27
Additional Paid-In Capital	123.84	123.84	123.84	-
Retained Earnings	350.05	300.22	227.65	-
Treasury Stock	-0.08	-0.08	-0.08	-
Shareholders' Equity	631.65	581.82	509.25	50.27
Total Liabilities & Equity	4,791	4,305	3,628	1,704
Total Debt	685.18	689.75	723	645.75
Net Cash (Debt)	146.23	449.19	489.32	-163.63
Net Cash Growth	-	-8.20%	-	-
Net Cash Per Share	57.34	176.14	209.40	-
Filing Date Shares Outstanding	2.3	2.3	2.28	-
Total Common Shares Outstanding	2.3	2.3	2.28	-
Working Capital	463.12	593.11	765.99	-
Book Value Per Share	274.54	252.88	223.32	-
Tangible Book Value	490.61	560	481.98	-
Tangible Book Value Per Share	213.24	243.40	211.36	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.